PURPOSE:Systemic chemotherapy has improved the survival of patients with hepatoblastoma (HB). INT-0098 Intergroup Liver Tumor Study demonstrated that patients with HB treated with either cisplatin/fluorouracil/vincristine (CFV) or cisplatin/doxorubicin (CD) had a similar survival. The Children's Oncology Group adopted the less toxic CFV as the standard regimen for treating HB. However, international cooperative groups still favor the CD combination. We therefore decided to revisit the role of doxorubicin for the treatment of HB. METHODS: Outcomes of patients with HB on the INT-0098 study were reviewed with an emphasis on the postevent survival time for both regimens to elucidate the role of doxorubicin in their retrieval. RESULTS:Sixty-four of the 173 randomly assigned patients had an event. Of these, 55 experienced progression or recurrence after initial treatment. Eleven (31%) of 36 patients treated withCFV were successfully retrieved with a doxorubicin-containing regimen and surgery and remain alive at last contact, whereas only one (6%) of 18 patients treated with CD was alive after retrieval therapy. CONCLUSION:CFV is effective for stage I or II HB. Doxorubicin can be omitted as part of initial therapy in the majority of these patients, potentially limiting the long-term cardiac toxicities, without compromising outcome. Doxorubicin is effective in rescuing patients with recurrent disease after CFV and should be incorporated as a means of intensifying initial therapy for advanced-stage, nonmetastatic HB. Outcome of patients with metastatic disease at diagnosis is poor, and improving their survival will require new therapeutic approaches.
RCT Entities:
PURPOSE: Systemic chemotherapy has improved the survival of patients with hepatoblastoma (HB). INT-0098 Intergroup Liver Tumor Study demonstrated that patients with HB treated with either cisplatin/fluorouracil/vincristine (CFV) or cisplatin/doxorubicin (CD) had a similar survival. The Children's Oncology Group adopted the less toxic CFV as the standard regimen for treating HB. However, international cooperative groups still favor the CD combination. We therefore decided to revisit the role of doxorubicin for the treatment of HB. METHODS: Outcomes of patients with HB on the INT-0098 study were reviewed with an emphasis on the postevent survival time for both regimens to elucidate the role of doxorubicin in their retrieval. RESULTS: Sixty-four of the 173 randomly assigned patients had an event. Of these, 55 experienced progression or recurrence after initial treatment. Eleven (31%) of 36 patients treated with CFV were successfully retrieved with a doxorubicin-containing regimen and surgery and remain alive at last contact, whereas only one (6%) of 18 patients treated with CD was alive after retrieval therapy. CONCLUSION:CFV is effective for stage I or II HB. Doxorubicin can be omitted as part of initial therapy in the majority of these patients, potentially limiting the long-term cardiac toxicities, without compromising outcome. Doxorubicin is effective in rescuing patients with recurrent disease after CFV and should be incorporated as a means of intensifying initial therapy for advanced-stage, nonmetastatic HB. Outcome of patients with metastatic disease at diagnosis is poor, and improving their survival will require new therapeutic approaches.
Authors: D von Schweinitz; D J Byrd; H Hecker; P Weinel; U Bode; D Bürger; R Erttmann; D Harms; H Mildenberger Journal: Eur J Cancer Date: 1997-07 Impact factor: 9.162
Authors: F Sasaki; T Matsunaga; M Iwafuchi; Y Hayashi; H Ohkawa; M Ohira; T Okamatsu; T Sugito; Y Tsuchida; A Toyosaka; N Nagahara; H Nishihira; Y Hata; J Uchino; K Misugi; N Ohnuma Journal: J Pediatr Surg Date: 2002-06 Impact factor: 2.545
Authors: J A Ortega; E C Douglass; J H Feusner; M Reynolds; J J Quinn; M J Finegold; J E Haas; D R King; W Liu-Mares; M G Sensel; M D Krailo Journal: J Clin Oncol Date: 2000-07 Impact factor: 44.544
Authors: J Pritchard; J Brown; E Shafford; G Perilongo; P Brock; C Dicks-Mireaux; J Keeling; A Phillips; A Vos; J Plaschkes Journal: J Clin Oncol Date: 2000-11-15 Impact factor: 44.544
Authors: S Suita; T Tajiri; H Takamatsu; H Mizote; A Nagasaki; Y Inomata; T Hara; J Okamura; S Miyazaki; K Kawakami; H Eguchi; M Tsuneyoshi Journal: J Pediatr Surg Date: 2004-02 Impact factor: 2.545
Authors: Rajkumar Venkatramani; Wayne L Furman; Joerg Fuchs; Steven W Warmann; Marcio H Malogolowkin Journal: Paediatr Drugs Date: 2012-08-01 Impact factor: 3.022
Authors: Alexander J Neuwelt; Y Jeffrey Wu; Narcyz Knap; Marcin Losin; Edward A Neuwelt; Michael A Pagel; Steven Warmann; Joerg Fuchs; Piotr Czauderna; Michal Wozniak Journal: Neoplasia Date: 2009-10 Impact factor: 5.715
Authors: Harold N Lovvorn; Dan Ayers; Zhiguo Zhao; Melissa Hilmes; Pinki Prasad; Myrick C Shinall; Barry Berch; Wallace W Neblett; James A O'Neill Journal: J Pediatr Surg Date: 2010-01 Impact factor: 2.545
Authors: Verena Ellerkamp; Sorin Armeanu-Ebinger; Julia Wenz; Steven W Warmann; Juergen Schäfer; Peter Ruck; Joerg Fuchs Journal: PLoS One Date: 2011-08-10 Impact factor: 3.240